Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2164252 | Update on Cancer Therapeutics | 2007 | 13 Pages |
Abstract
Antiandrogens are an important class of therapeutic agents for treatment of prostate cancer. While traditionally used as a second-line hormonal therapy following androgen deprivation treatment, they have been studied in a number of other settings. Antiandrogens continue to be a class of highly selective agents with relatively little toxicity compared to non-hormonal therapies for advanced disease. Compounds in development that target androgen receptor activation hold great promise for men with prostate cancer.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Russell Z. Szmulewitz, Edwin M. Posadas,